These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 24845945)

  • 1. Comprehensive in vitro Proarrhythmia Assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative.
    Cavero I; Holzgrefe H
    Expert Opin Drug Saf; 2014 Jun; 13(6):745-58. PubMed ID: 24845945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CiPA: Ongoing testing, future qualification procedures, and pending issues.
    Cavero I; Holzgrefe H
    J Pharmacol Toxicol Methods; 2015; 76():27-37. PubMed ID: 26159293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress.
    Colatsky T; Fermini B; Gintant G; Pierson JB; Sager P; Sekino Y; Strauss DG; Stockbridge N
    J Pharmacol Toxicol Methods; 2016; 81():15-20. PubMed ID: 27282641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac voltage-gated ion channels in safety pharmacology: Review of the landscape leading to the CiPA initiative.
    Huang H; Pugsley MK; Fermini B; Curtis MJ; Koerner J; Accardi M; Authier S
    J Pharmacol Toxicol Methods; 2017 Sep; 87():11-23. PubMed ID: 28408211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive in vitro Proarrhythmia Assay (CiPA): Pending issues for successful validation and implementation.
    Cavero I; Guillon JM; Ballet V; Clements M; Gerbeau JF; Holzgrefe H
    J Pharmacol Toxicol Methods; 2016; 81():21-36. PubMed ID: 27233533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proarrhythmia liability assessment and the comprehensive in vitro Proarrhythmia Assay (CiPA): An industry survey on current practice.
    Authier S; Pugsley MK; Koerner JE; Fermini B; Redfern WS; Valentin JP; Vargas HM; Leishman DJ; Correll K; Curtis MJ
    J Pharmacol Toxicol Methods; 2017 Jul; 86():34-43. PubMed ID: 28223123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CiPA challenges and opportunities from a non-clinical, clinical and regulatory perspectives. An overview of the safety pharmacology scientific discussion.
    Wallis R; Benson C; Darpo B; Gintant G; Kanda Y; Prasad K; Strauss DG; Valentin JP
    J Pharmacol Toxicol Methods; 2018; 93():15-25. PubMed ID: 29958940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm.
    Fermini B; Hancox JC; Abi-Gerges N; Bridgland-Taylor M; Chaudhary KW; Colatsky T; Correll K; Crumb W; Damiano B; Erdemli G; Gintant G; Imredy J; Koerner J; Kramer J; Levesque P; Li Z; Lindqvist A; Obejero-Paz CA; Rampe D; Sawada K; Strauss DG; Vandenberg JI
    J Biomol Screen; 2016 Jan; 21(1):1-11. PubMed ID: 26170255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
    Zhang X; Guo L; Zeng H; White SL; Furniss M; Balasubramanian B; Lis E; Lagrutta A; Sannajust F; Zhao LL; Xi B; Wang X; Davis M; Abassi YA
    J Pharmacol Toxicol Methods; 2016; 81():201-16. PubMed ID: 27282640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonclinical cardiovascular safety of pitolisant: comparing International Conference on Harmonization S7B and Comprehensive in vitro Pro-arrhythmia Assay initiative studies.
    Ligneau X; Shah RR; Berrebi-Bertrand I; Mirams GR; Robert P; Landais L; Maison-Blanche P; Faivre JF; Lecomte JM; Schwartz JC
    Br J Pharmacol; 2017 Dec; 174(23):4449-4463. PubMed ID: 28941245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative.
    Li Z; Ridder BJ; Han X; Wu WW; Sheng J; Tran PN; Wu M; Randolph A; Johnstone RH; Mirams GR; Kuryshev Y; Kramer J; Wu C; Crumb WJ; Strauss DG
    Clin Pharmacol Ther; 2019 Feb; 105(2):466-475. PubMed ID: 30151907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recording of multiple ion current components and action potentials in human induced pluripotent stem cell-derived cardiomyocytes via automated patch-clamp.
    Mann SA; Heide J; Knott T; Airini R; Epureanu FB; Deftu AF; Deftu AT; Radu BM; Amuzescu B
    J Pharmacol Toxicol Methods; 2019; 100():106599. PubMed ID: 31228558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting.
    Strauss DG; Gintant G; Li Z; Wu W; Blinova K; Vicente J; Turner JR; Sager PT
    Ther Innov Regul Sci; 2019 Jul; 53(4):519-525. PubMed ID: 30157676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biophysics and Molecular Biology of Cardiac Ion Channels for the Safety Pharmacologist.
    Pugsley MK; Curtis MJ; Hayes ES
    Handb Exp Pharmacol; 2015; 229():149-203. PubMed ID: 26091640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 13th Annual Meeting of the Safety Pharmacology Society: focus on novel technologies and safety pharmacology frontiers.
    Cavero I
    Expert Opin Drug Saf; 2014 Sep; 13(9):1271-81. PubMed ID: 25054438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of disease state on arrhythmic event detection by action potential modelling in cardiac safety pharmacology.
    Christophe B; Crumb WJ
    J Pharmacol Toxicol Methods; 2019; 96():15-26. PubMed ID: 30580044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early drug development: assessment of proarrhythmic risk and cardiovascular safety.
    Lester RM; Olbertz J
    Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1611-1618. PubMed ID: 27718759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
    Yang X; Papoian T
    J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSAHi study: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes -assessment of inter-facility and cells lot-to-lot-variability.
    Nozaki Y; Honda Y; Watanabe H; Saiki S; Koyabu K; Itoh T; Nagasawa C; Nakamori C; Nakayama C; Iwasaki H; Suzuki S; Washio I; Takahashi E; Miyamoto K; Yamanishi A; Endo H; Shinozaki J; Nogawa H; Kunimatsu T
    Regul Toxicol Pharmacol; 2016 Jun; 77():75-86. PubMed ID: 26884090
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Boulay E; Troncy E; Jacquemet V; Huang H; Pugsley MK; Downey AM; Venegas Baca R; Authier S
    Int J Toxicol; 2024; 43(4):357-367. PubMed ID: 38477622
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.